Published in
Elsevier, The Lancet Oncology, 8(23), p. 1066-1077, 2022
DOI: 10.1016/s1470-2045(22)00339-4
Links
Tools
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
Journal article published in 2022 by
Alison Sehgal,
Daanish Hoda,
Peter A. Riedell 
,
Nilanjan Ghosh,
Mehdi Hamadani,
Gerhard C. Hildebrandt,
John E. Godwin,
Patrick M. Reagan,
Nina Wagner-Johnston,
James Essell,
Rajneesh Nath,
Scott R. Solomon,
Rebecca Champion,
Edward Licitra,
Suzanne Fanning
and other authors.
,
Nilanjan Ghosh,
Mehdi Hamadani,
Gerhard C. Hildebrandt,
John E. Godwin,
Patrick M. Reagan,
Nina Wagner-Johnston,
James Essell,
Rajneesh Nath,
Scott R. Solomon,
Rebecca Champion,
Edward Licitra,
Suzanne Fanning
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 